JP2017531673A5 - - Google Patents

Info

Publication number

JP2017531673A5

JP2017531673A5 JP2017521992A JP2017521992A JP2017531673A5 JP 2017531673 A5 JP2017531673 A5 JP 2017531673A5 JP 2017521992 A JP2017521992 A JP 2017521992A JP 2017521992 A JP2017521992 A JP 2017521992A JP 2017531673 A5 JP2017531673 A5 JP 2017531673A5

Authority

JP

Japan

Prior art keywords

effective amount

filovirus

individual

clarithromycin

medicament according

Prior art date

2015-10-23

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Granted

Links

• Espacenet
• Global Dossier
• Discuss

• 241000711950 Filoviridae Species 0.000 claims description 19
• 239000003814 drug Substances 0.000 claims description 14
• 230000003612 virological effect Effects 0.000 claims description 14
• 230000005764 inhibitory process Effects 0.000 claims description 11
• 230000029812 viral genome replication Effects 0.000 claims description 11
• 229960002626 clarithromycin Drugs 0.000 claims description 9
• AGOYDEPGAOXOCK-KCBOHYOISA-N clarithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@](C)([C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)OC)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 AGOYDEPGAOXOCK-KCBOHYOISA-N 0.000 claims description 9
• 241001115402 Ebolavirus Species 0.000 claims description 8
• ZWBTYMGEBZUQTK-PVLSIAFMSA-N [(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,32-tetrahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-1'-(2-methylpropyl)-6,23-dioxospiro[8,33-dioxa-24,27,29-triazapentacyclo[23.6.1.14,7.05,31.026,30]tritriaconta-1(32),2,4,9,19,21,24,26,30-nonaene-28,4'-piperidine]-13-yl] acetate Chemical compound CO[C@H]1\C=C\O[C@@]2(C)Oc3c(C2=O)c2c4NC5(CCN(CC(C)C)CC5)N=c4c(=NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)c(O)c2c(O)c3C ZWBTYMGEBZUQTK-PVLSIAFMSA-N 0.000 claims description 6
• 229960000885 rifabutin Drugs 0.000 claims description 6
• 230000003321 amplification Effects 0.000 claims description 5
• 238000003199 nucleic acid amplification method Methods 0.000 claims description 5
• 150000007523 nucleic acids Chemical class 0.000 claims description 5
• 102000039446 nucleic acids Human genes 0.000 claims description 5
• 108020004707 nucleic acids Proteins 0.000 claims description 5
• 208000024891 symptom Diseases 0.000 claims description 5
• 230000002195 synergetic effect Effects 0.000 claims description 5
• 241001115401 Marburgvirus Species 0.000 claims description 4
• 208000007136 Filoviridae Infections Diseases 0.000 claims 2
• CAOTVXGYTWCKQE-RZTFFZPQSA-N (7s)-3-(4-chlorophenyl)-n-(pyridin-4-ylmethyl)adamantane-1-carboxamide Chemical compound C1=CC(Cl)=CC=C1C1(C2)CC(C3)(C(=O)NCC=4C=CN=CC=4)C[C@H]2CC3C1 CAOTVXGYTWCKQE-RZTFFZPQSA-N 0.000 claims 1
• OECLPECEPAYMGH-UHFFFAOYSA-N 3-(4-chlorophenyl)adamantane-1-carboxylic acid Chemical compound C1C(C(=O)O)(C2)CC(C3)CC1CC32C1=CC=C(Cl)C=C1 OECLPECEPAYMGH-UHFFFAOYSA-N 0.000 claims 1
• 241000700605 Viruses Species 0.000 claims 1
• 150000001408 amides Chemical class 0.000 claims 1
• 238000000034 method Methods 0.000 description 25
• 150000001875 compounds Chemical class 0.000 description 8
• 125000000217 alkyl group Chemical group 0.000 description 6
• 230000003115 biocidal effect Effects 0.000 description 5
• 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 4
• UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 4
• 229910052736 halogen Inorganic materials 0.000 description 4
• 150000002367 halogens Chemical class 0.000 description 4
• 229910052739 hydrogen Inorganic materials 0.000 description 4
• 239000001257 hydrogen Substances 0.000 description 4
• 239000003242 anti bacterial agent Substances 0.000 description 3
• 229940088710 antibiotic agent Drugs 0.000 description 3
• 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 description 2
• 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 2
• 125000004093 cyano group Chemical group *C#N 0.000 description 2
• 125000001188 haloalkyl group Chemical group 0.000 description 2
• 125000002768 hydroxyalkyl group Chemical group 0.000 description 2
• 238000012986 modification Methods 0.000 description 2
• 230000004048 modification Effects 0.000 description 2
• 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 description 2
• 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
• 150000003839 salts Chemical class 0.000 description 2
• 239000007787 solid Substances 0.000 description 2
• 239000007909 solid dosage form Substances 0.000 description 2
• 125000001424 substituent group Chemical group 0.000 description 2
• 229930189077 Rifamycin Natural products 0.000 description 1
• 238000003556 assay Methods 0.000 description 1
• 239000002775 capsule Substances 0.000 description 1
• 239000003120 macrolide antibiotic agent Substances 0.000 description 1
• 239000000203 mixture Substances 0.000 description 1
• 229960003292 rifamycin Drugs 0.000 description 1
• HJYYPODYNSCCOU-ODRIEIDWSA-N rifamycin SV Chemical compound OC1=C(C(O)=C2C)C3=C(O)C=C1NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@H](C)[C@@H](OC)\C=C\O[C@@]1(C)OC2=C3C1=O HJYYPODYNSCCOU-ODRIEIDWSA-N 0.000 description 1